3.16
제노바이오틱스로 알려진 제약 물질은 주로 친유성이며 비이온화되어 있습니다. 이를 통해 세포막과 같은 지질 이중층에 침투하여 세포내 표적 수용체와 상호작용할 수 있습니다. 친유성 약물은 생물학적 장벽을 넘어 의도한 작용 부위에 도달하는 데 이점이 있습니다. 그러나 친유성…
약물은 대부분 친유성이며 비이온화된 특수 생체이물입니다. 이를 통해 약물은 지질 이중층을 통과하여 세포의 표적 수용체에 도달할 수 있습니다.
그러나 지유성 약물은 사구체 여과액에서 혈액으로 빠르게 재흡수되기 때문에 제한된 신장 배설 능력을 보이는 경우가 많습니다. 체내에 축적되면 약물 작용이 연장되고 독성 반응이 촉진됩니다.
이를 방지하기 위해 약물을 친수성 유도체로 생체 형질전환하여 소변을 통한 배양을 강화할 수 있습니다.
여러 신체 조직이 약물을 대사할 수 있지만, 간은 생체 내 변형의 주요 부위입니다.
약물 생체변형은 순차적으로 발생하고 특정 세포 효소에 의해 촉매되는 두 가지 주요 반응을 포함합니다.
1상 반응은 이화작용이며 기능화를 포함하는 반면, 2상 반응은 동화작용이며 접합을 포함합니다.
신진 대사 과정은 종종 약물의 생물학적 활성을 종료하지만 prodrugs에서는 향상된 활성이 달성됩니다.
View the full transcript and gain access to JoVE Core videos
Q1: Why do lipophilic drugs need to be biotransformed?
Lipophilic drugs are poorly eliminated by the kidneys because they are rapidly reabsorbed from the glomerular filtrate back into the bloodstream through drug elimination by renal route tubular reabsorption. This reabsorption causes drug accumulation in the body, prolonging effects and triggering toxic reactions. Biotransformation converts lipophilic drugs into hydrophilic derivatives, enabling efficient elimination through urine and preventing harmful accumulation.
Q2: What is the role of the liver in drug biotransformation?
The liver is the primary site for drug biotransformation, though other body tissues can also metabolize drugs. Specialized enzymes in the liver catalyze the sequential phase I and phase II reactions that convert lipophilic drugs into water-soluble metabolites. This hepatic metabolism is essential for preparing drugs for efficient elimination from the body.
Q3: How do phase I and phase II reactions differ in drug metabolism?
Phase I reactions are catabolic and involve functionalization, introducing or exposing functional groups like hydroxyl, amino, or carboxyl groups to the drug molecule. Phase II reactions are anabolic and involve conjugation, adding water-soluble molecules such as glucuronic acid, sulfate, or glutathione. Together, these sequential reactions progressively increase drug water solubility for elimination.
Q4: What chemical properties allow drugs to cross cell membranes?
Drugs are predominantly lipophilic and nonionized, allowing them to pass through lipid bilayers and reach intracellular target receptors. This lipophilic nature is advantageous for crossing biological barriers and reaching sites of action. However, this same property limits renal excretion, necessitating biotransformation into hydrophilic derivatives for elimination.
Q5: How does biotransformation affect drug activity?
Biotransformation generally terminates a drug's biological activity by converting it into inactive metabolites. However, prodrugs represent an exception where biotransformation enhances activity rather than eliminating it. In prodrugs, metabolism converts an inactive compound into an active form, leading to improved therapeutic outcomes and more effective treatment.
Q6: What functional groups are introduced during phase I drug metabolism?
Phase I reactions introduce or expose functional groups such as hydroxyl (-OH), amino (-NH2), or carboxyl (-COOH) groups to the drug molecule. These functionalization reactions create more polar metabolites than the parent drug, preparing the molecule for phase II conjugation reactions that further increase water solubility.
Q7: What molecules are typically added during phase II conjugation reactions?
Phase II conjugation reactions add larger, water-soluble molecules to drugs or their phase I metabolites, including glucuronic acid, sulfate, or glutathione. These conjugation reactions significantly increase the drug's water solubility and prepare it for efficient elimination from the body through urine.